Atlas Trials

Viridian Therapeutics, Inc.

8 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Viridian Therapeutics, Inc.

RecordFirmDate
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) (NCT07155668)Viridian Therapeutics, Inc.2025-07-01
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) (NCT06812325)Viridian Therapeutics, Inc.2025-02-03
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) (NCT06625411)Viridian Therapeutics, Inc.2024-08-27
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) (NCT06625398)Viridian Therapeutics, Inc.2024-08-27
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (NCT06384547)Viridian Therapeutics, Inc.2024-05-23
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 (NCT06179875)Viridian Therapeutics, Inc.2024-01-31
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (NCT06021054)Viridian Therapeutics, Inc.2023-11-01
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) (NCT05176639)Viridian Therapeutics, Inc.2022-11-16

Track Viridian Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.